Products

Osimertinib Intermediate 1, also known as (R)-N-(4-(2-(dimethylamino)ethyl)phenyl)-3-(2-(prop-2-yn-1-yloxy)ethoxy)propanamide, is a key intermediate compound in the synthesis of osimertinib, which is an anticancer drug used in the treatment of non-small cell lung cancer.Osimertinib Intermediate 1 plays a crucial role in the construction of the molecular structure of osimertinib. It serves as a building block during the synthesis process, allowing for the attachment of various chemical groups that contribute to the final structure and activity of osimertinib. Its specific chemical structure provides the necessary functional groups and linkages that are essential for subsequent steps in the synthesis.By carefully controlling the reactions and conditions during its synthesis, Osimertinib Intermediate 1 can be produced in high yields and with high purity. This is of great importance in the pharmaceutical industry to ensure the quality and consistency of the final drug product.Once Osimertinib Intermediate 1 is synthesized, it undergoes further chemical transformations to form the final structure of osimertinib. These transformations typically involve coupling reactions, functional group manipulations, and purification steps to remove any impurities that may have been introduced during the synthesis.The final product, osimertinib, is an irreversible inhibitor of mutated forms of the epidermal growth factor receptor (EGFR) enzyme, which is highly expressed in non-small cell lung cancer. By specifically targeting and inhibiting these mutated forms of EGFR, osimertinib effectively suppresses the growth and proliferation of cancer cells, leading to tumor regression and improved patient outcomes.Osimertinib has shown significant clinical efficacy in patients with non-small cell lung cancer and has been approved by regulatory authorities for use in several countries. Its development and production rely on the successful synthesis of Osimertinib Intermediate 1, which serves as a critical intermediate in the overall synthesis process.In summary, Osimertinib Intermediate 1 is an essential building block in the synthesis of osimertinib, an effective anticancer drug for the treatment of non-small cell lung cancer. Its precise chemical structure and reactivity allow for the efficient construction of osimertinib's molecular framework, ultimately leading to its potent anticancer activity.